Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Projects
Publications
Prizes
Spin-Offs
Media
Activities
Search by expertise, name or affiliation
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
RUBY Investigators
Clinic of Gynecology and Obstetrics
Charles University
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Endometrial Neoplasms
100%
Placebos
59%
Confidence Intervals
58%
Microsatellite Instability
39%
Progression-Free Survival
39%
Carboplatin
24%
Paclitaxel
21%
Programmed Cell Death 1 Receptor
15%
Response Evaluation Criteria in Solid Tumors
13%
DNA Mismatch Repair
12%
Population
12%
Body Surface Area
12%
Survival
11%
Alopecia
11%
Combination Drug Therapy
10%
Random Allocation
10%
Nausea
9%
Immunotherapy
9%
Fatigue
9%
Research Personnel
7%
Randomized Controlled Trials
7%
Safety
6%
Therapeutics
3%
Neoplasms
3%